MNKD - MannKind Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

MannKind Corporation

30930 Russell Ranch Road
Suite 300
Westlake Village, CA 91362
United States

Full Time Employees225

Key Executives

NameTitlePayExercisedYear Born
Dr. Michael E. CastagnaCEO & Director675.7kN/A1977
Mr. Steven B. BinderChief Financial Officer520.45kN/A1963
Dr. David B. ThomsonExec. VP, Gen. Counsel & Sec.581.28kN/A1967
Mr. James Patrick McCauley Jr., J.D., M.B.A.Chief Commercial Officer731.64kN/A1966
Dr. David M. Kendall M.D.Chief Medical Officer685.23kN/A1962
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company has a licensing and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.

Corporate Governance

MannKind Corporation’s ISS Governance QualityScore as of July 29, 2019 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.